Continuing Allston Troubles Mean Another Brief Shutdown, Delay For Lumizyme Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
An FDA "complete response" letter in relation to Genzyme's sBLA for Lumizyme says plant problems must be resolved before approval.